XML 88 R67.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Commitments and Contingencies - Additional Information (Detail) - USD ($) | 1 Months Ended |  |  |
--- | --- | --- | --- | ---
Dec. 31, 2021 | Sep. 30, 2021 | Dec. 31, 2023 | Dec. 31, 2022 | Apr. 30, 2013
Commitment And Contingencies [Line Items] |  |  |  |  |
Contingent liabilities |  |  | $ 0 | $ 0 |
Eddingpharm Purchase Agreement [Member] |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |
Purchase agreement obligation |  |  |  |  | $ 5,000,000
Incyte Agreement [Member] | Global and U.S. [Member] |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |
Development costs associated with clinical trials |  | 45.00% |  |  |
Incyte Agreement [Member] | Non-Refundable Cash Payments [Member] |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |
Upfront milestone payable | $ 117,000,000 | $ 117,000,000 |  |  |
Incyte Agreement [Member] | Equity Investment [Member] |  |  |  |  |
Commitment And Contingencies [Line Items] |  |  |  |  |
Upfront milestone payable |  | $ 35,000,000 |  |  |

X
- Definition Commitment and contingencies. + References No definition available. + Details
Name: | sndx_CommitmentAndContingenciesLineItems
Namespace Prefix: | sndx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development costs associated with clinical trials. + References No definition available. + Details
Name: | sndx_DevelopmentCostsAssociatedWithClinicalTrials
Namespace Prefix: | sndx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payments. + References No definition available. + Details
Name: | sndx_UpfrontPayments
Namespace Prefix: | sndx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -SubTopic 30 -Topic 805 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + References No definition available. + Details
Name: | us-gaap_PurchaseObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | us-gaap_RegistrationPaymentArrangementByArrangementAxis=sndx_SeriesB1PurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=sndx_CollaborationAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=sndx_GlobalAndUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=sndx_NonRefundableCashPaymentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FairValueByAssetClassAxis=us-gaap_EquityMethodInvestmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |